ReviewBMC infectious diseases2022
Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.
Review in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Genomic analysis of five new mycobacteriophages belonging to the F, G, K, and P clusters.3 Biotech · 2025Article
- Genomic survey reveals no detectable bacteriophage activity in Mycobacterium bovis across a large population.FEMS microbiology ecology · 2025Article
- Phage Therapy forInfectious disease reports · 2025Article
- Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery.Virology journal · 2025Article
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Human Gut Bacteriophageome: Insights Into Drug Resistance Mechanisms in Tuberculosis.Interdisciplinary perspectives on infectious diseases · 2025Review
- Review
- Complete genome sequence of Wildflower, an O cluster mycobacteriophage.Microbiology resource announcements · 2024Article
- The Biological Characteristics ofInternational journal of molecular sciences · 2024Article
- Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight againstInternational journal of molecular sciences · 2024Review
- Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.European journal of microbiology & immunology · 2024Review
- Ending tuberculosis: challenges and opportunities.Frontiers in tuberculosis · 2024Review
- Activity of Bacteriophage D29 Loaded on Nanoliposomes against Macrophages Infected withDiseases (Basel, Switzerland) · 2023Article
- Classification and characterisation of extracellular vesicles-related tuberculosis subgroups and immune cell profiles.Journal of cellular and molecular medicine · 2023Article
- Experimental Studies of the Liposomal Form of Lytic Mycobacteriophage D29 for the Treatment of Tuberculosis Infection.Microorganisms · 2023Article
- Classification of tuberculosis-related programmed cell death-related patient subgroups and associated immune cell profiling.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis (M. tuberculosis) is a highly infectious disease and worldwide health problem. Based on the WHO TB report, 9 million active TB cases are emerging, leading to 2 million deaths each year. The recent emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains emphasizes the necessity to improve novel therapeutic plans. Among the various developing antibacterial approaches, phage therapy is thought to be a precise hopeful resolution. Mycobacteriophages are viruses that infect bacteria such as Mycobacterium spp., containing the M. tuberculosis complex. Phages and phage-derived proteins can act as promising antimicrobial agents. Also, phage cocktails can broaden the spectrum of lysis activity against bacteria. Recent researches have also shown the effective combination of antibiotics and phages to defeat the infective bacteria. There are limitations and concerns about phage therapy. For example, human immune response to phage therapy, transferring antibiotic resistance genes, emerging resistance to phages, and safety issues. So, in the present study, we introduced mycobacteriophages, their use as therapeutic agents, and their advantages and limitations as therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.